Pfizer RFP COVID-19 Vaccine Development for Low- and Middle-Income Countries (LMICs)

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Monday 19th, December 2022

External Deadline: Saturday 31st, December 2022


Pfizer Global Medical Grants (GMG) and BioNTech support the global healthcare community’s independent research initiatives to improve patient outcomes in areas of unmet medical need that are aligned with our medical and/or scientific strategies.

The competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. Organizations may submit an application addressing the research areas as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer and BioNTech must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Date RFP Issued: February 17, 2022

Geographic Scope: Global with preference given to organizations with a presence in an LMIC

NOTE: Requests from China, Hong Kong, Macau, and Taiwan are ineligible as these markets are outside the Pfizer/BioNTech collaboration.

Clinical Area: Vaccine Preventable Diseases – COVID-19

Link to full RFP: COVID-19 Vaccine Development for LMICs

Application Due Date: December 31, 2022 (Grant applications may be submitted throughout the year and application reviews and decisions will be completed on a rolling basis)

Specific Area of Interest: The intent of this RFP is to support COVID-19 vaccine development for LMICs. The support provided by Pfizer will be through the provision of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) for comparator studies. No funding will be provided.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: February 17, 2022